Health Care
Benefits administration and biopharmaceutical sales: Reported FY2025 Results
UnitedHealth Group and AbbVie illustrate why health care cannot be assessed with one revenue-quality assumption. This source-linked study separates reported observations from interpretation and compares only the selected issuers.
The business models
UnitedHealth Group and AbbVie illustrate why health care cannot be assessed with one revenue-quality assumption. Premium and service revenue have a different cost structure from prescription-medicine revenue, and acquired research charges require specific accounting context.
Selected reported observations
UnitedHealth Group Incorporated (UNH), year ended 2025-12-31 — Revenue: 447,600 USD million (rounded from USD 447.6 billion); Earnings from operations: 19,000 USD million (rounded from USD 19.0 billion); Operating cash flow: 19,700 USD million (rounded from USD 19.7 billion). AbbVie Inc. (ABBV), year ended 2025-12-31 — Net revenues: 61,160 USD million; Operating earnings: 15,075 USD million; Net earnings attributable to AbbVie: 4,226 USD million.
Analytical interpretation
Keep reported EPS, adjusted EPS, product revenue and medical or research costs in their respective definitions. Do not turn large revenue into a prediction of shareholder returns. An insurer and health-services group can report very large revenue while retaining a much smaller earnings share. Costs of medical care and the mix of services affect that relationship. The adjusted EPS figure is a supplementary measure, so it is shown beside rather than substituted for the GAAP result. Total revenue combines medicines with different commercial trajectories. Product-level sales therefore provide useful context for the group total. Acquired IPR&D and recurring R&D are separate expense captions; adding them together without explaining the distinction can obscure how acquisitions affect reported earnings.
Comparison boundaries
Reimbursement, medical utilization, product exclusivity, clinical development and acquired intangible assets create different exposures. Two issuer cases do not yield a sector-wide margin.
Sources and method
Figures are selected historical annual observations from the linked company reports. Fiscal 2025 means the issuer’s own fiscal label, not a common calendar interval. Dollar amounts retain the million-dollar source unit, and source-rounded figures remain marked as rounded. The analysis is editorial interpretation; it is not company guidance, a sector return estimate or an investment recommendation. Source review date: 2026-11-15.